EUS-RFA is feasible, safe, and provides durable local control of BD-IPMNs with WF/HRS in patients unsuitable for surgery or declining resection. These results support EUS-RFA as a promising therapeutic option in carefully selected patients. Larger prospective studies are needed to refine selection criteria and confirm long-term oncologic benefit.
Barras et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: